ImmunityBio, Inc. IBRX

ImmunityBio's single approved drug, ANKTIVA, generated $44.2m of net product revenue in the quarter ending 31 March 2026, up from $16.5m in the same period a year earlier, according to the company's 10-Q filed on 7 May 2026. The filing states that during the three months ended 31 March 2026 and 2025, product revenue was generated from US sales of ANKTIVA, the therapy the FDA approved in April 2024.

ImmunityBio is a biotechnology company whose revenue currently rests on that one approved therapy. The surrounding research effort is heavy: the company reported $190.1m of research and development expense in its 10-K for the year ending 31 December 2024. A business with a single approved product and a research budget of that size depends on whether sales and the pipeline can grow faster than cash leaves the building.

The 10-Q for the period ending 31 March 2026 records a net loss attributable to the parent of $632.8m and an operating loss of $69.8m, a gap the filing does not narrate for a casual reader. Diluted loss per share was $0.62 across a weighted average of 1.03bn diluted shares. The balance sheet showed $646.6m of assets against $1.52bn of liabilities, leaving stockholders' equity attributable to the parent at minus $870.0m. Cash and equivalents stood at $205.2m, operating activities used $75.4m, and purchases of property and equipment were $1.8m. Inventory was $547,000 net, with a separately reported $5.0m increase in inventories on the cash statement.

The supplied source rail is SEC EDGAR: the submissions and company-facts JSON feeds, the EDGAR filing index for CIK 1326110, the 10-Q, an 8-K dated 18 May 2026, and six Form 4 insider filings dated 10 June 2026. No TradingView or chart route was supplied with this file, so there are no price levels, ranges or candles to describe; the evidence here is documentary rather than tape-based. The 8-K sets out a supply agreement under which JBL manufactures a Product, ImmunityBio funds all development and regulatory work, and no payment is due to JBL before FDA approval, with exclusive territory rights then running ten years from that approval.

What changed most clearly is the revenue line, which nearly tripled year on year on ANKTIVA sales, alongside the financing history the filing notes: after the April 2024 approval, Oberland purchased additional Revenue Interests on 13 May 2024 for a gross $100.0m, less $3.1m of issuance costs. What the evidence does not prove is the reason the net loss so far exceeds the operating loss, the direction or size of the 10 June insider transactions, or whether the JBL Product will clear the FDA at all. A fuller file would need the items below the operating line, the specific Form 4 transaction details, and any regulatory timeline for the JBL Product.